Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolus (EOLS) Asset Writedowns and Impairment (2019 - 2025)

Historic Asset Writedowns and Impairment for Evolus (EOLS) over the last 7 years, with Q3 2025 value amounting to $2.2 million.

  • Evolus' Asset Writedowns and Impairment rose 14859.39% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 17243.55%. This contributed to the annual value of $2.4 million for FY2024, which is 7006.94% up from last year.
  • As of Q3 2025, Evolus' Asset Writedowns and Impairment stood at $2.2 million, which was up 14859.39% from $703000.0 recorded in Q2 2025.
  • Over the past 5 years, Evolus' Asset Writedowns and Impairment peaked at $2.2 million during Q3 2025, and registered a low of -$297000.0 during Q2 2021.
  • Moreover, its 5-year median value for Asset Writedowns and Impairment was $465000.0 (2022), whereas its average is $528421.1.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first tumbled by 7660.15% in 2021, then skyrocketed by 81860.47% in 2024.
  • Evolus' Asset Writedowns and Impairment (Quarter) stood at $88000.0 in 2021, then surged by 167.05% to $235000.0 in 2022, then plummeted by 63.4% to $86000.0 in 2023, then skyrocketed by 818.6% to $790000.0 in 2024, then skyrocketed by 179.75% to $2.2 million in 2025.
  • Its Asset Writedowns and Impairment stands at $2.2 million for Q3 2025, versus $703000.0 for Q2 2025 and $1.1 million for Q1 2025.